Indian Pharma Market to Grow by 12-14% Up to 2023
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
The National Institution for Transforming India, also called NITI Aayog, was formed via a resolution of the Union Cabinet on January 1, 2015. NITI Aayog is the premier policy ‘Think Tank’ of the Government of India, providing both directional and policy inputs. While designing strategic and long term policies and programmes for the Government of India, NITI Aayog also provides relevant technical advice to the Centre and States.
The Government of India, in keeping with its reform agenda, constituted the NITI Aayog to replace the Planning Commission instituted in 1950. This was done in order to better serve the needs and aspirations of the people of India. An important evolutionary change from the past, NITI Aayog acts as the quintessential platform of the Government of India to bring States to act together in national interest, and thereby fosters Cooperative Federalism.
At the core of NITI Aayog’s creation are two hubs – Team India Hub and the Knowledge and Innovation Hub. The Team India Hub leads the engagement of states with the Central government, while the Knowledge and Innovation Hub builds NITI’s think-tank capabilities. These hubs reflect the two key tasks of the Aayog.
NITI Aayog is also developing itself as a State of the Art Resource Centre, with the necessary resources, knowledge and skills, that will enable it to act with speed, promote research and innovation, provide strategic policy vision for the government, and deal with contingent issues.
Contact:
Address: Sansad Marg, Sansad Marg Area, New Delhi, Delhi 110001, India
Website: http://niti.gov.in/content/overview
Email: vinodk.paul@gov.in
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports. Given the…
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated…
Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output…
See our Cookie Privacy Policy Here
